Amanta Healthcare Ltd Upgraded to Hold by MarketsMOJO Amid Technical and Financial Improvements

Technical Trend Shift Spurs Upgrade

The primary catalyst for the rating change is the shift in Amanta Healthcare’s technical trend from sideways to mildly bullish. Weekly technical indicators such as the Moving Average Convergence Divergence (MACD) and Bollinger Bands have turned bullish, signalling positive momentum in the stock price. The Dow Theory also supports this mild bullishness on both weekly and monthly timeframes. However, some mixed signals remain, with the weekly Relative Strength Index (RSI) showing bearish tendencies and On-Balance Volume (OBV) indicating mild bearishness on a weekly basis. Despite these nuances, the overall technical outlook has improved sufficiently to warrant a more optimistic stance.

Financial Trend: Strong Quarterly Performance

Amanta Healthcare’s financial performance in Q3 FY25-26 has been a significant factor in the upgrade. The company reported its highest quarterly net sales at ₹74.49 crores, accompanied by a 73.88% growth in Profit After Tax (PAT) for the nine months ended December 2025, reaching ₹10.75 crores. Operating profit to interest coverage ratio also improved to 3.04 times, indicating better debt servicing ability in the short term. These results underscore a positive financial trend, with profits rising by 189% over the past year, despite the absence of a reported stock return for the same period.

Valuation Metrics Reflect Attractive Investment Case

From a valuation perspective, Amanta Healthcare presents an attractive profile. The company’s Return on Capital Employed (ROCE) stands at a healthy 14%, complemented by a low Enterprise Value to Capital Employed ratio of 2.1. These metrics suggest efficient capital utilisation and reasonable pricing relative to the company’s asset base. The stock currently trades at ₹137.75, down 1.82% from the previous close of ₹140.30, and remains below its 52-week high of ₹154.85 but comfortably above the 52-week low of ₹93.10. This valuation backdrop supports the Hold rating, signalling potential for moderate appreciation without excessive risk.

Quality Assessment: Mixed Long-Term Fundamentals

While recent quarters have shown promising financial results, Amanta Healthcare’s long-term fundamental strength remains weak. The company has experienced a negative compound annual growth rate (CAGR) of -2.00% in net sales over the last five years, signalling challenges in sustaining growth. Additionally, the company’s debt profile raises concerns, with a high Debt to EBITDA ratio of 3.11 times, indicating limited ability to service debt over the long term. These factors temper the overall quality rating and justify a cautious Hold rather than a more aggressive Buy recommendation.

Institutional Investor Confidence Bolsters Outlook

Institutional investors have increased their stake in Amanta Healthcare by 1.38% over the previous quarter, now collectively holding 13.72% of the company’s shares. This growing institutional participation is a positive sign, as these investors typically possess superior analytical resources and a longer-term investment horizon. Their increased involvement suggests confidence in the company’s improving fundamentals and technical outlook, lending further support to the upgraded rating.

Stock Performance Relative to Sensex

Amanta Healthcare’s stock has outperformed the Sensex over recent periods, reinforcing the positive momentum. The stock delivered a 3.92% return over the past week compared to the Sensex’s 0.17%. Over one month, the stock surged 26.98%, vastly outperforming the Sensex’s 5.04% gain. Year-to-date, the stock has risen 26.72%, while the Sensex declined by 9.63%. These returns highlight the stock’s resilience and potential for further gains, despite the micro-cap classification and inherent volatility.

Balancing Positives and Risks for Investors

In summary, Amanta Healthcare’s upgrade to a Hold rating reflects a balanced view of its current position. The improved technical trend and strong quarterly financial results provide a solid foundation for cautious optimism. Attractive valuation metrics and increased institutional interest further support this stance. However, investors should remain mindful of the company’s weak long-term sales growth and elevated debt levels, which pose risks to sustained performance.

Given these factors, the Hold rating suggests that while the stock is no longer a sell, it may not yet warrant a full buy recommendation. Investors seeking exposure to the Pharmaceuticals & Biotechnology sector should consider Amanta Healthcare as a potential candidate for portfolio inclusion, but with an awareness of its micro-cap volatility and fundamental challenges.

Outlook and Market Positioning

Looking ahead, Amanta Healthcare’s ability to maintain its recent financial momentum and improve its debt servicing capacity will be critical to further rating upgrades. Continued positive technical signals and institutional support could drive incremental gains in the stock price. However, the company must address its long-term growth trajectory to attract a broader investor base and achieve a stronger Mojo Grade than the current Hold rating with a Mojo Score of 50.0.

As of 6 May 2026, the stock trades at ₹137.75, with a 52-week trading range between ₹93.10 and ₹154.85. Investors should monitor upcoming quarterly results and technical developments closely to reassess the stock’s investment potential.

Conclusion

Amanta Healthcare Ltd’s recent upgrade from Sell to Hold by MarketsMOJO reflects a nuanced improvement across four key parameters: quality, valuation, financial trend, and technicals. While the company’s technical outlook has turned mildly bullish and financial results have strengthened significantly, long-term fundamental weaknesses and debt concerns remain. This balanced assessment positions the stock as a Hold, signalling cautious optimism for investors willing to navigate the micro-cap’s risks and rewards.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today